Cancer‐testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis
Abstract Introduction Cancer testis (CT) antigens are attractive targets for cancer immunotherapy because of their expression restriction and immunogenicity. The acrosin binding protein (ACRBP) is a member of CT antigens. This study aimed to evaluate ACRBP expression and immunogenicity in ovarian ca...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-12-01
|
| Series: | Immunity, Inflammation and Disease |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iid3.534 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849420798249402368 |
|---|---|
| author | Lina Lin Weixia Nong Bin Luo Yingying Ge Xia Zeng Feng Li Rong Fan Qingmei Zhang Xiaoxun Xie |
| author_facet | Lina Lin Weixia Nong Bin Luo Yingying Ge Xia Zeng Feng Li Rong Fan Qingmei Zhang Xiaoxun Xie |
| author_sort | Lina Lin |
| collection | DOAJ |
| description | Abstract Introduction Cancer testis (CT) antigens are attractive targets for cancer immunotherapy because of their expression restriction and immunogenicity. The acrosin binding protein (ACRBP) is a member of CT antigens. This study aimed to evaluate ACRBP expression and immunogenicity in ovarian cancer (OC). Methods The expression level of ACRBP in OC tissues, normal ovarian tissues, and cell lines was detected via quantitative real‐time polymerase chain reaction (qRT‐PCR) and immunohistochemistry. We determined the levels of ACRBP antigen and antibody in serum samples collected from patients with OC and healthy donors using enzyme‐linked immunosorbent assays (ELISA), the level of ACRBP in cell‐cultured medium was also tested. Results ACRBP mRNA and protein expressions were upregulated in OC tissues relative to normal tissue, especially highly expressed in epithelial ovarian cancer (EOC). Moreover, ACRBP expression was significantly correlated with International Federation of Gynecology and Obstetrics (FIGO) stage and chemosensitivity. Serological analysis showed that anti‐ACRBP antibody was detected in the sera of 16 of the 56 (28.5%) patients with OC but not in healthy donors. The area under the receiver operating characteristic curve for ACRBP antibody was 0.802 (95% confidence interval [CI]: 0.708–0.876), and the sensitivity and specificity for ACRBP antibody was 85.71% and 55.0%, respectively. Kaplan–Meier analysis revealed that the overall survival (OS) and disease‐free survival (DFS) in OC patients with high ACRBP expression were significantly lower than those with low expression (p = 0.040, p = 0.021). However, ACRBP antibody level was not associated with prognosis. Conclusion ACRBP expression was upregulated in OC tissues and induced humoral immune response in patients with OC, suggesting that ACRBP is a potential prognostic biomarker and a target of tumor immunotherapy for OC. |
| format | Article |
| id | doaj-art-5d2c0dd73fbd4bcb99c51a4afd50e335 |
| institution | Kabale University |
| issn | 2050-4527 |
| language | English |
| publishDate | 2021-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Immunity, Inflammation and Disease |
| spelling | doaj-art-5d2c0dd73fbd4bcb99c51a4afd50e3352025-08-20T03:31:38ZengWileyImmunity, Inflammation and Disease2050-45272021-12-01941759177010.1002/iid3.534Cancer‐testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosisLina Lin0Weixia Nong1Bin Luo2Yingying Ge3Xia Zeng4Feng Li5Rong Fan6Qingmei Zhang7Xiaoxun Xie8Department of Histology and Embryology, School of Preclinical Medicine Guangxi Medical University Nanning ChinaDepartment of Histology and Embryology, School of Preclinical Medicine Guangxi Medical University Nanning ChinaDepartment of Histology and Embryology, School of Preclinical Medicine Guangxi Medical University Nanning ChinaDepartment of Histology and Embryology, School of Preclinical Medicine Guangxi Medical University Nanning ChinaDepartment of Histology and Embryology, School of Preclinical Medicine Guangxi Medical University Nanning ChinaDepartment of Histology and Embryology, School of Preclinical Medicine Guangxi Medical University Nanning ChinaDepartment of Histology and Embryology, School of Preclinical Medicine Guangxi Chinese Medicine University Nanning ChinaDepartment of Histology and Embryology, School of Preclinical Medicine Guangxi Medical University Nanning ChinaDepartment of Histology and Embryology, School of Preclinical Medicine Guangxi Medical University Nanning ChinaAbstract Introduction Cancer testis (CT) antigens are attractive targets for cancer immunotherapy because of their expression restriction and immunogenicity. The acrosin binding protein (ACRBP) is a member of CT antigens. This study aimed to evaluate ACRBP expression and immunogenicity in ovarian cancer (OC). Methods The expression level of ACRBP in OC tissues, normal ovarian tissues, and cell lines was detected via quantitative real‐time polymerase chain reaction (qRT‐PCR) and immunohistochemistry. We determined the levels of ACRBP antigen and antibody in serum samples collected from patients with OC and healthy donors using enzyme‐linked immunosorbent assays (ELISA), the level of ACRBP in cell‐cultured medium was also tested. Results ACRBP mRNA and protein expressions were upregulated in OC tissues relative to normal tissue, especially highly expressed in epithelial ovarian cancer (EOC). Moreover, ACRBP expression was significantly correlated with International Federation of Gynecology and Obstetrics (FIGO) stage and chemosensitivity. Serological analysis showed that anti‐ACRBP antibody was detected in the sera of 16 of the 56 (28.5%) patients with OC but not in healthy donors. The area under the receiver operating characteristic curve for ACRBP antibody was 0.802 (95% confidence interval [CI]: 0.708–0.876), and the sensitivity and specificity for ACRBP antibody was 85.71% and 55.0%, respectively. Kaplan–Meier analysis revealed that the overall survival (OS) and disease‐free survival (DFS) in OC patients with high ACRBP expression were significantly lower than those with low expression (p = 0.040, p = 0.021). However, ACRBP antibody level was not associated with prognosis. Conclusion ACRBP expression was upregulated in OC tissues and induced humoral immune response in patients with OC, suggesting that ACRBP is a potential prognostic biomarker and a target of tumor immunotherapy for OC.https://doi.org/10.1002/iid3.534ACRBPcancer‑testis antigendiagnostic markerimmunotherapyovarian cancer |
| spellingShingle | Lina Lin Weixia Nong Bin Luo Yingying Ge Xia Zeng Feng Li Rong Fan Qingmei Zhang Xiaoxun Xie Cancer‐testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis Immunity, Inflammation and Disease ACRBP cancer‑testis antigen diagnostic marker immunotherapy ovarian cancer |
| title | Cancer‐testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis |
| title_full | Cancer‐testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis |
| title_fullStr | Cancer‐testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis |
| title_full_unstemmed | Cancer‐testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis |
| title_short | Cancer‐testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis |
| title_sort | cancer testis antigen acrbp expression and serum immunoreactivity in ovarian cancer its association with prognosis |
| topic | ACRBP cancer‑testis antigen diagnostic marker immunotherapy ovarian cancer |
| url | https://doi.org/10.1002/iid3.534 |
| work_keys_str_mv | AT linalin cancertestisantigenacrbpexpressionandserumimmunoreactivityinovariancanceritsassociationwithprognosis AT weixianong cancertestisantigenacrbpexpressionandserumimmunoreactivityinovariancanceritsassociationwithprognosis AT binluo cancertestisantigenacrbpexpressionandserumimmunoreactivityinovariancanceritsassociationwithprognosis AT yingyingge cancertestisantigenacrbpexpressionandserumimmunoreactivityinovariancanceritsassociationwithprognosis AT xiazeng cancertestisantigenacrbpexpressionandserumimmunoreactivityinovariancanceritsassociationwithprognosis AT fengli cancertestisantigenacrbpexpressionandserumimmunoreactivityinovariancanceritsassociationwithprognosis AT rongfan cancertestisantigenacrbpexpressionandserumimmunoreactivityinovariancanceritsassociationwithprognosis AT qingmeizhang cancertestisantigenacrbpexpressionandserumimmunoreactivityinovariancanceritsassociationwithprognosis AT xiaoxunxie cancertestisantigenacrbpexpressionandserumimmunoreactivityinovariancanceritsassociationwithprognosis |